Neutrophil–lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment

Mizutani, Takashi; Shirabe, Ken; Mano, Yohei; Muto, Jun; Toshima, Takeo; Umemoto, Yuichiro; Fukuhara, Takasuke; Uchiyama, Hideaki; Ikegami, Toru; Yoshizumi, Tomoharu; Soejima, Yuji; Maehara, Yoshihiko

doi:10.1016/j.jhep.2012.08.017

Cited by 414 publications

(385 citation statements)

References 29 publications

Supporting

Mentioning

374

Contrasting

Unclassified

Order By: Relevance

“…The neutrophillymphocyte ratio (NLR), an indicator of systemic inflammatory status, has been recognized as a prognostic indicator in various malignancies (45)(46)(47)(48)(49). Halazun et al reported that HCC recipients with a pretransplant NLR > 5 had a significantly increased incidence of post-transplant HCC recurrence (62% vs 14%, p<0.001) and inferior recurrence-free and overall (50).…”

Section: Discussionmentioning

confidence: 99%

A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant Recipients

Agopian

Harlander-Locke

Zarrinpar

et al. 2015

Journal of the American College of Surgeons

223

176

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant Recipients

Agopian

Harlander-Locke

Zarrinpar

et al. 2015

Journal of the American College of Surgeons

223

176

View full text Add to dashboard Cite

show abstract

“…These inflammatory cytokines may establish and keep a tumor microenvironment favoring aggressive tumor behavior. An elevated NLR is considered to be associated with elevated circulating concentrations of these cytokines, which offers an insight into mechanisms underlying an elevated NLR (30,31). Nevertheless, the cutoff points of NLR proposed in previous studies differ, including NLR thresholds of 2.3, 4.02 or 5 in gastric cancer (14,32,33), 0.38, 2.4 or 3 in colorectal cancer (15,34,35), 2.3 or 2.5 in NSCLC (10,36), and consensus has not been established.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of preoperative neutrophil-lymphocyte ratio is superior to platelet-lymphocyte ratio for survival in patients who underwent complete resection of thymic carcinoma

Yuan¹,

Gao²,

Mu³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Preoperative neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have prognostic value in patients with various operable tumors. The aim of our study was to determine whether NLR and PLR are predictive of survival in thymic carcinoma patients after complete resection. Results: Univariate analysis found that a high level of NLR was associated with lower disease-free survival (DFS) (HR: 3.385, 95% CI: 1.073-10.678, P=0.037) and lower overall survival (OS) (HR: 12.836, 95% CI:1.615-101.990, P=0.016). The optimal NLR threshold of 4.1 could stratify the patients with high risk of recurrence or metastasis (P=0.026) and death (P=0.006). Meanwhile, the NLR value of >4.1 in those patients was associated with bigger tumor size (P=0.035) and more advanced Masaoka stages (P=0.040) compared with NLR ≤4.1. However, the PLR and other variables were not significantly associated with survival in thymic carcinoma patients. Conclusions:The preoperative NLR of >4.1 was significantly associated with larger tumor size, more advanced Masaoka stages and reduced DFS and OS, but was not an independent predictor of survival in thymic carcinoma patients after complete resection.

show abstract

“…In similar studies, researchers have investigated the use of NLR as a prognostic factor. Motomura et al (30) found there was a correlation between elevated NLR and upregulated interleukin (IL)-17 concentration in serum and peritumoral regions. IL-17 is a proinflammatory cytokine that promotes HCC growth (31).…”

Section: Univariate Analysismentioning

confidence: 99%

Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib

Yuan

Liang

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Sorafenib is currently the only efficient molecular targeted therapy for hepatocellular carcinoma (HCC), although its effect is relatively moderate and variable between individuals. The present study aimed to evaluate the significance of peripheral blood neutrophils in the prognosis of HCC patients treated with sorafenib. A total of 464 patients with HCC were treated with sorafenib at Zhongshan Hospital (Shanghai, China) between January 1st, 2008 and December 31st, 2012, among which 120 patients were enrolled in the study. The optimal cutoff point for low vs. high neutrophil count (3.65x10 9 ) was obtained from a receiver operating characteristic curve. Overall survival (OS) was compared between the patients with low and high peripheral neutrophil counts. Univariate and multivariate analyses were used to explore the prognostic factors associated with OS in the patients treated with sorafenib. A nomogram model was also performed to predict the OS times of these patients. The median OS time was 9.0 months (95% confidence interval, 5.9-12.1 months) in the whole group of patients, with 1-, 2-and 3-year OS rates of 36, 24 and 16%, respectively. Using a cutoff level of 3.65x10 9 neutrophils/l, the median OS time was longer in the group of patients with a low peripheral neutrophil count than in those with a high peripheral neutrophil count (11.5 vs. 5.0 months, respectively; P<0.001). The multivariate analysis showed that peripheral neutrophil count, α-fetoprotein level and tumor size were independent prognostic factors for OS. In addition, using the nomogram model for the prediction of OS, the Harrell's c-index was 0.79. Therefore, it was concluded that a lower peripheral blood neutrophil count was associated with a better prognosis following treatment with sorafenib therapy.

show abstract

Neutrophil–lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment

Cited by 414 publications

References 29 publications

A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant Recipients

A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant Recipients

Prognostic value of preoperative neutrophil-lymphocyte ratio is superior to platelet-lymphocyte ratio for survival in patients who underwent complete resection of thymic carcinoma

Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib

Contact Info

Product

Resources

About